Minerva Neurosciences
Open
$4.46
Prev. Close
$4.47
High
$4.46
Low
$4.38
Market Snapshot
$189.11M
-0.5
0.19
7
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Recently from Cashu
Minerva Neurosciences Partners with Aidoc to Enhance Neurodiagnostic Capabilities and Patient Care
Advancing Neurodiagnostic Capabilities through Strategic Partnerships Aidoc, a leader in clinical AI technology, forges strategic partnerships with Cercare Medical and Circle CVI to enhance its neuros…
Minerva Neurosciences Appoints Carlos Martin as Chief Commercial Officer for Strategic Growth
Neurvati Neurosciences Strengthens Leadership with Appointment of Chief Commercial Officer Neurvati Neurosciences, a subsidiary of Blackstone Life Sciences, announces the appointment of Carlos Martin…
Minerva Neurosciences Appoints Carlos Martin as Chief Commercial Officer to Enhance Leadership
Neurvati Neurosciences Strengthens Leadership with Appointment of Carlos Martin as Chief Commercial Officer Neurvati Neurosciences, a prominent player in the biopharmaceutical sector, announces the ap…
Minerva Neurosciences Strengthens Advisory Board with Renowned Neurologist for Neurodegenerative Disease Therapies
NewcelX Appoints Renowned Neurologist to Scientific Advisory Board, Enhancing Its Commitment to Neurodegenerative Disease Therapies NewcelX Ltd., a Zurich-based biotechnology firm, strengthens its Sci…